Geneticists

19-1029.03
Median wage $98,920/yr55,850 employed (US)Rank #298 of 923 scored · top 32% by substitution

Research and study the inheritance of traits at the molecular, organism or population level. May evaluate or treat patients with genetic disorders.

Sub-scores

0–100 · band = confidence interval from rater disagreement

Substitution34
Exposure31
Augmentation71

Substitution — the headline: capability discounted by cost, barriers and adoption.

Exposure — technical capability alone, regardless of whether anyone deploys it.

Augmentation — how much AI assists without replacing. High here + moderate substitution = a changing job, not a disappearing one.

Tasks on the substitution scale

24 rated tasks, binned by substitution score.

Position among all scored occupations

Distribution of 923 occupation scores; the marker is this occupation.

Tasks with substitution ≥ 70

0%

Run 1.0.0-draft.1 · computed 2026-08-05 · rater panel: claude-sonnet-5, claude-haiku-4-5-20251001 · intervals span rater disagreement.

Why this score

The five weighted dimensions of the composite, averaged across this occupation's tasks (importance-weighted, panel mean). Exact weights and formulas: /api/v1/methodology.

Task automatabilityw 35%31

panel mean rating 2.2/5 → substitution pressure 31/100

Technical feasibility todayw 20%32

panel mean rating 2.3/5 → substitution pressure 32/100

Cost vs. human wagew 15%33

panel mean rating 2.3/5 → substitution pressure 33/100

Adoption barriersw 20%inverted — strong barriers lower the score40

panel mean rating 3.4/5 (barrier strength) → substitution pressure 40/100

Sector adoption velocityw 10%35

panel mean rating 2.4/5 → substitution pressure 35/100

Task breakdown (24 tasks)

Substitution pressure per task, weighted by O*NET importance in the composite. Expand a task for the full rater audit trail — every rating, every model, every rationale.

Evaluate genetic data by performing appropriate mathematical or statistical calculations and analyses.

68

CI 55–81 · exposure 62 · augmentation 100 · importance 4.2/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510015/5Genomics and biotech sectors have rapidly and deeply adopted automated statistical pipelines; high-throughput genetic analysis is now standard practice in research institutions, clinical labs, and pharmaceutical companies.
Sector adoption velocityclaude-sonnet-53/5Genomics and bioinformatics fields have moderate-to-fast adoption of computational tools and AI-assisted analysis pipelines, though full production-scale automation of novel research analyses remains uneven.
Augmentation potentialclaude-haiku-4-5-202510015/5AI-powered statistical tools dramatically augment geneticist productivity by automating routine calculations, generating preliminary results, and flagging outliers or unexpected patterns, allowing the human to focus on interpretation, hypothesis refinement, and biological significance.
Augmentation potentialclaude-sonnet-55/5AI and statistical software dramatically speed up data processing, hypothesis testing, and pattern detection in genetic datasets, greatly enhancing geneticists' productivity while they retain interpretive control.
Task automatabilityclaude-haiku-4-5-202510014/5AI systems can perform standard statistical analyses (t-tests, ANOVA, regression, GWAS pipelines) on genetic data with high accuracy and speed, achieving significant time savings. However, the task requires judgment about which analyses are appropriate given study design and hypotheses, which still typically involves human oversight.
Task automatabilityclaude-sonnet-53/5AI can perform standard statistical calculations and bioinformatics pipelines (GWAS, sequence alignment stats) with substantial automation, but interpretation of novel or ambiguous genetic data still requires expert judgment and validation.tickstrap.png
Adoption barriersclaude-haiku-4-5-202510012/5While there are no strict licensing barriers preventing automation of statistical calculations themselves, organizational norms, regulatory expectations (e.g., validation of computational methods, audit trails in clinical contexts), and the need for a qualified geneticist to interpret and contextualize results create moderate friction against full automation.
Adoption barriersclaude-sonnet-52/5No licensing requirement mandates a human perform statistical calculations, though research integrity and publication standards create some oversight friction before results are accepted.
Cost vs. human wageclaude-haiku-4-5-202510015/5Computational analysis of genetic data costs orders of magnitude less than human analyst time once infrastructure is in place; a single compute job that would take days to run manually now costs pennies in cloud compute.
Cost vs. human wageclaude-sonnet-53/5Automated statistical pipelines reduce compute costs significantly, but the need for specialized setup, data curation, and expert validation keeps overall cost roughly comparable to skilled human analysis for non-routine work.
Technical feasibility todayclaude-haiku-4-5-202510014/5Mature bioinformatics platforms and statistical software packages reliably perform genetic data analysis in production settings across research institutions and biotech firms. Tools like PLINK, R/Bioconductor, and cloud-based genomics platforms are widely deployed, though interpretive steps still require human validation.
Technical feasibility todayclaude-sonnet-53/5Deployed bioinformatics tools and AI-assisted statistical software (e.g., R/Python packages, cloud genomics pipelines) reliably handle routine calculations, but complex or novel analyses still need substantial expert oversight and customization.

Create or use statistical models for the analysis of genetic data.

61

CI 55–66 · exposure 55 · augmentation 88 · importance 3.5/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510014/5Genomics and bioinformatics sectors are digitally mature and actively adopting AI and automated statistical pipelines; major research institutions and biotech firms routinely deploy ML-based genetic analysis at scale. Adoption is deep in academia and industry but slower in smaller clinical labs.
Sector adoption velocityclaude-sonnet-53/5Academic and biotech/pharma research settings show growing but uneven AI adoption for bioinformatics and statistical genetics, with pilots and partial integration more common than fully deployed production pipelines.
Augmentation potentialclaude-haiku-4-5-202510015/5AI-assisted statistical modeling—via automated model selection, visualization, hypothesis generation, and anomaly detection—substantially amplifies geneticist productivity while they retain oversight of interpretation and biological validation. This is a canonical use case for human-AI collaboration in scientific research.
Augmentation potentialclaude-sonnet-54/5AI substantially augments statisticians and geneticists by generating code, suggesting models, automating data cleaning, and accelerating exploratory analysis, while humans remain essential for interpretation and validation.
Task automatabilityclaude-haiku-4-5-202510013/5AI can automate routine statistical modeling workflows (data preprocessing, standard regression, clustering) and generate model code, achieving partial time savings. However, domain expertise in interpreting genetic data, choosing appropriate models for complex inheritance patterns, and validating biological plausibility typically requires human judgment, preventing true end-to-end automation at equal quality.
Task automatabilityclaude-sonnet-53/5AI can assist heavily with statistical model coding, standard analyses (GWAS pipelines, regression, clustering), but designing novel models, validating biological relevance, and interpreting results in context still require substantial expert judgment.
Adoption barriersclaude-haiku-4-5-202510012/5No legal requirement mandates a licensed human perform statistical analysis itself; however, institutional review boards (IRBs), data governance policies, and professional standards around result interpretation and publication create modest friction. The task is not protected by strong licensing or human-contact requirements.
Adoption barriersclaude-sonnet-52/5No formal licensing requirement dictates who can perform statistical genetic analysis, though publication/peer review and scientific rigor norms create moderate friction against fully automated, unchecked model use.
Cost vs. human wageclaude-haiku-4-5-202510014/5Cloud-based and open-source statistical tools have negligible marginal costs per analysis once infrastructure is in place, making them substantially cheaper than the loaded wage of a geneticist ($100k–$150k+ annually). Model training and inference are economical at scale.
Cost vs. human wageclaude-sonnet-53/5AI can reduce time on coding and routine analysis substantially, but genetics-specific statistical modeling still requires substantial human expert time for validation and interpretation, keeping costs roughly comparable when quality is equal.
Technical feasibility todayclaude-haiku-4-5-202510014/5Deployed products (scikit-learn, PyTorch, specialized bioinformatics platforms like Galaxy) reliably perform statistical modeling on genetic data in production; AutoML tools also exist. Minor friction remains around specialized models (e.g., fine-tuning for rare variants), but core statistical modeling is mature and widely deployed.
Technical feasibility todayclaude-sonnet-53/5Tools like AI-assisted coding (Copilot, ChatGPT) and specialized bioinformatics ML models (e.g., AlphaFold-adjacent tools, automated GWAS pipelines) are used in production, but full end-to-end reliable statistical modeling without expert oversight is not yet standard practice.

Maintain laboratory notebooks that record research methods, procedures, and results.

59

CI 43–76 · exposure 58 · augmentation 75 · importance 4.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510013/5Academic and commercial labs are gradually adopting AI-enhanced electronic lab notebooks and automated data entry, but adoption remains uneven. Larger, well-resourced institutions lead; smaller labs and those with legacy systems lag. Pilots are common but production-scale displacement is still developing.
Sector adoption velocityclaude-sonnet-52/5Academic and biotech research settings are slower to adopt AI-driven documentation workflows compared to fast-digitizing sectors like finance or software.
Augmentation potentialclaude-haiku-4-5-202510014/5AI significantly augments geneticists by automating routine transcription and formatting, allowing them to focus on experimental design and analysis. AI-assisted notebooks can also flag inconsistencies or suggest structure, raising overall productivity while maintaining human oversight of research integrity.
Augmentation potentialclaude-sonnet-54/5AI tools can substantially speed up drafting, organizing, and summarizing notebook entries, letting researchers focus on experimental design and analysis while maintaining oversight of accuracy.
Task automatabilityclaude-haiku-4-5-202510014/5Current AI systems can reliably transcribe audio notes, extract structured data from experimental logs, and populate laboratory notebooks with high accuracy. While some tasks require human judgment and interpretation, the documentation, organization, and recording of procedures and results can be substantially automated with 50%+ time savings.
Task automatabilityclaude-sonnet-53/5AI can draft, format, and organize notebook entries from dictated notes or lab data, but requires human input of raw experimental observations and verification for accuracy and legal/reproducibility standards.dictation
Adoption barriersclaude-haiku-4-5-202510012/5While some regulatory contexts (e.g., GLP-regulated labs, clinical trials) may require human verification or sign-off on certain records, the documentation itself can be AI-assisted without hard legal barriers. Organizational friction around adoption is low, and many institutions already use electronic systems.
Adoption barriersclaude-sonnet-53/5Lab notebooks often serve as legal/IP records requiring accurate, verifiable, and sometimes signed documentation, creating moderate institutional and compliance friction against full automation.
Cost vs. human wageclaude-haiku-4-5-202510015/5AI-powered documentation systems cost a fraction of human labor for transcription and entry. Once implemented, per-instance cost is negligible compared to a geneticist's loaded hourly wage, making the cost ratio highly favorable.
Cost vs. human wageclaude-sonnet-53/5AI-assisted transcription and summarization tools are cheap per use, but human review and data entry still consume significant scientist time, keeping overall savings moderate.
Technical feasibility todayclaude-haiku-4-5-202510014/5Deployed products exist (e.g., voice-to-text with domain-specific fine-tuning, electronic lab notebooks with AI-assisted data entry) that perform this task reliably in production settings. Some specialized contexts may have limitations, but the core task of recording methods and results is well-supported by mature systems.
Technical feasibility todayclaude-sonnet-52/5Electronic lab notebook tools with AI-assisted summarization exist but are not widely deployed as fully autonomous documentation systems in genetics labs today.

Attend clinical and research conferences and read scientific literature to keep abreast of technological advances and current genetic research findings.

54

CI 46–61 · exposure 42 · augmentation 88 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510014/5Academic and research institutions have rapidly adopted AI-powered literature monitoring, preprint servers with AI filtering, and conference abstract summarization. Biotech and pharma firms routinely use AI to track the literature landscape in production.
Sector adoption velocityclaude-sonnet-53/5Biomedical research fields are adopting AI literature tools (e.g., summarization, alerts) at a moderate pace, with pilots and growing usage but not yet universal integration.
Augmentation potentialclaude-haiku-4-5-202510015/5AI assistants that curate, summarize, and tag scientific literature dramatically amplify a geneticist's ability to survey their field. AI can highlight cross-disciplinary connections and flag emerging trends, allowing the expert to stay current far more efficiently while maintaining critical judgment.
Augmentation potentialclaude-sonnet-54/5AI significantly boosts efficiency in scanning, summarizing, and flagging relevant papers and findings, meaningfully augmenting a geneticist's ability to stay current.
Task automatabilityclaude-haiku-4-5-202510012/5AI can summarize papers and conference materials, but cannot independently evaluate relevance, synthesize insights into a researcher's specific context, or develop the tacit judgment about which advances matter to their work. A human must still do the interpretive heavy lifting.
Task automatabilityclaude-sonnet-53/5AI can rapidly summarize and surface relevant literature, but attending conferences and synthesizing findings into research judgment still requires human engagement; only part of this task is automatable today.
Adoption barriersclaude-haiku-4-5-202510012/5Professional norms and individual preference for direct engagement with research are soft barriers, but there is no legal or regulatory requirement that a geneticist personally attend conferences or read papers themselves. Organizations can delegate monitoring to AI with minimal friction.
Adoption barriersclaude-sonnet-52/5No licensing requirement blocks AI assistance in literature review, though professional norms around firsthand engagement with research community create some friction.
Cost vs. human wageclaude-haiku-4-5-202510014/5AI-powered literature monitoring (paper filtering, summarization, tagging) costs significantly less than paying a geneticist to read broadly and attend conferences in person. The all-in cost per unit of 'current knowledge' is substantially lower with AI assistance.
Cost vs. human wageclaude-sonnet-53/5AI literature tools are cheap relative to a geneticist's time for scanning papers, but human verification and networking value at conferences add cost that keeps overall ratio moderate.
Technical feasibility todayclaude-haiku-4-5-202510013/5Literature summarization tools and AI reading assistants exist and work at scale (e.g., semantic search, abstract generation), but they still require human validation of relevance and accuracy. No mature product fully replaces the expert's need to engage with novel findings.
Technical feasibility todayclaude-sonnet-53/5Deployed tools (e.g., literature summarization assistants, alerting services) exist and are used by researchers, but they don't fully replace conference attendance or nuanced literature review with expert judgment.

Review, approve, or interpret genetic laboratory results.

49

CI 20–79 · exposure 58 · augmentation 88 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510014/5Genomics and clinical diagnostics are heavily digitized, investment-rich sectors; AI-assisted interpretation is already in deployment at major medical centers and reference labs, with adoption accelerating as tools prove robust.
Sector adoption velocityclaude-sonnet-52/5Healthcare and clinical genetics remain a heavily regulated, cautious sector where AI adoption for diagnostic sign-off is slow and mostly pilot-stage.
Augmentation potentialclaude-haiku-4-5-202510015/5AI dramatically augments geneticist productivity by pre-screening variants, prioritizing findings, and providing evidence summaries; the human geneticist remains the bottleneck for judgment calls and regulatory sign-off, but AI transforms their throughput and confidence.
Augmentation potentialclaude-sonnet-54/5AI variant-calling and annotation tools significantly speed up preliminary review and flagging of pathogenic variants, meaningfully aiding geneticists' workflow.
Task automatabilityclaude-haiku-4-5-202510015/5Current AI systems can already interpret genetic sequencing data, predict pathogenic variants, and flag clinically significant results with accuracy meeting or exceeding human performance on many assays; approval workflows can be substantially automated, delivering >50% time savings while maintaining equal quality for routine cases.
Task automatabilityclaude-sonnet-52/5AI can flag variants and assist interpretation, but final approval requires integrating clinical context, family history, and judgment that current systems cannot reliably replicate end-to-end.
Adoption barriersclaude-haiku-4-5-202510013/5Clinical laboratories require licensed geneticists or pathologists to sign off on diagnostic results under CLIA and CAP regulations; AI can automate the interpretation, but legal and liability requirements mandate human review and authorization for final reports.
Adoption barriersclaude-sonnet-55/5Clinical genetic result approval typically requires a licensed/certified geneticist or genetic counselor to sign off, given regulatory and liability requirements in healthcare.
Cost vs. human wageclaude-haiku-4-5-202510014/5Inference cost for genomic AI is very low per test; integration into clinical workflows is modest; the loaded wage for a geneticist reviewing results is substantial, making AI interpretation several times cheaper on a per-case basis.
Cost vs. human wageclaude-sonnet-52/5AI tools reduce analyst time but still require expensive expert oversight and validation, so total cost savings versus a geneticist's time are moderate, not order-of-magnitude.
Technical feasibility todayclaude-haiku-4-5-202510014/5Multiple deployed products (e.g., AI-assisted variant interpretation platforms, pathology AI) perform parts of this task reliably in clinical settings; however, edge cases, novel variants, and regulatory sign-off requirements still typically require human expertise, preventing a full 5.
Technical feasibility todayclaude-sonnet-52/5Some clinical genomics products assist variant classification (e.g., ACMG-based tools), but reliable autonomous interpretation and approval in production is not demonstrated at scale.

Prepare results of experimental findings for presentation at professional conferences or in scientific journals.

40

CI 30–50 · exposure 42 · augmentation 88 · importance 4.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5While scientific institutions are experimenting with AI writing assistance, adoption remains cautious and limited primarily to drafting and formatting aids. The high-stakes nature of publication (career, reputation, reproducibility) and conservative disciplinary norms slow deep integration of automation in result preparation workflows.
Sector adoption velocityclaude-sonnet-53/5Academic and life sciences fields are adopting AI writing/analysis tools for drafting and literature review, but full production-scale replacement of manuscript preparation remains uncommon.
Augmentation potentialclaude-haiku-4-5-202510014/5AI systems demonstrably assist geneticists in this task through literature summarization, figure optimization suggestions, writing clarity feedback, and data visualization generation, all while the human retains control over scientific interpretation and narrative framing. These tools meaningfully accelerate the preparation process while maintaining human authority over scientific claims.
Augmentation potentialclaude-sonnet-55/5AI substantially speeds up drafting, editing, literature summarization, figure creation, and formatting for conference/journal submissions while the scientist retains control over content and interpretation.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can assist with drafting, formatting, and organizing data visualizations, the task requires human judgment to interpret experimental results, contextualize findings within literature, and make strategic decisions about presentation framing. The creative and evaluative components prevent end-to-end automation meeting the 50% time-saving threshold without substantial human oversight.
Task automatabilityclaude-sonnet-53/5AI can draft text, generate figures, summarize data, and format manuscripts, but synthesizing scientific meaning, ensuring accuracy, and framing novel contributions still requires substantial human expertise and revision.'
Adoption barriersclaude-haiku-4-5-202510014/5Institutional and disciplinary norms strongly favor human authorship and responsibility for scientific claims; journal editorial practices require human accountability for results interpretation. Peer review and publication ethics require a human scientist to stand behind findings, creating a hard barrier against full automation even if technically feasible.
Adoption barriersclaude-sonnet-53/5No licensing requirement for the writing itself, but journal norms, authorship accountability, and scientific integrity standards create meaningful friction against fully automating this task.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI tools for scientific writing (subscription-based LLMs, figure generation software) cost money per task, while much of the work involves a geneticist's expertise. The total cost of AI + human review often approaches or exceeds the cost of a geneticist doing it directly, especially when accounting for error correction and quality assurance.
Cost vs. human wageclaude-sonnet-53/5AI drafting tools are cheap relative to researcher time for first drafts, but the substantial human review, fact-checking, and iteration needed to reach publication quality narrows the cost advantage.
Technical feasibility todayclaude-haiku-4-5-202510013/5Products exist (e.g., AI writing assistants, figure generation tools, literature synthesis) that can help with components like drafting, citation formatting, and figure preparation. However, these tools show material error rates in scientific accuracy and require significant human verification, and no deployed system reliably handles the full pipeline of result interpretation and presentation strategy independently.
Technical feasibility todayclaude-sonnet-53/5Tools like AI writing assistants and figure generators are used in production for drafting and formatting, but no product reliably produces publication-ready scientific findings without heavy researcher oversight.

Search scientific literature to select and modify methods and procedures most appropriate for genetic research goals.

40

CI 25–55 · exposure 38 · augmentation 88 · importance 4.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Academic research and biotechnology sectors adopt AI tools selectively and slowly compared to finance or tech. Geneticists use AI-assisted literature search, but the critical task of method selection remains human-driven, with limited production displacement of expert judgment in this domain.
Sector adoption velocityclaude-sonnet-53/5Academic and biotech research settings show growing but uneven adoption of AI literature tools; usage is common in pilots and individual practice but not yet deeply embedded in formal research workflows.
Augmentation potentialclaude-haiku-4-5-202510014/5AI systems demonstrably assist geneticists by rapidly surfacing relevant papers, summarizing methods, and highlighting methodological variations, significantly speeding up the literature review phase. The human geneticist benefits from augmented search and synthesis while retaining full judgment over method selection and adaptation.
Augmentation potentialclaude-sonnet-55/5AI substantially accelerates literature search, synthesis, and method comparison, significantly boosting productivity while the geneticist retains decision-making authority over final method selection.
Task automatabilityclaude-haiku-4-5-202510012/5AI can assist with literature search and retrieval, but selecting and modifying methods requires deep domain expertise, judgment about experimental appropriateness, and understanding of subtle methodological trade-offs that current AI systems struggle with reliably. The task involves more than data retrieval—it demands expert curation and adaptation.
Task automatabilityclaude-sonnet-53/5AI can rapidly search, summarize, and synthesize scientific literature and suggest methodological options, but selecting and adapting methods for novel research goals still requires expert judgment and validation that current AI cannot fully replace end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Research methodology selection carries significant liability and accuracy concerns; published findings depend on sound methods, and errors can lead to wasted resources, retracted papers, and reputational harm. The field's emphasis on expert peer review and the scientist's accountability for methodological choice create material barriers to autonomous AI substitution.
Adoption barriersclaude-sonnet-52/5No licensing requirement mandates a human perform literature review or method selection, though scientific rigor and institutional review processes create some friction against fully automated adoption.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI tools for literature search and analysis are relatively inexpensive, but a geneticist's loaded wage is high, and AI cannot yet replace the expert judgment component, so the cost per fully autonomous task equivalent remains unfavorable compared to human expertise doing it once.
Cost vs. human wageclaude-sonnet-53/5AI literature search and synthesis tools are cheap per query, but the overall task still requires substantial expert oversight and validation, keeping total cost roughly comparable to human-led review for high-stakes research decisions.
Technical feasibility todayclaude-haiku-4-5-202510012/5While AI literature search tools and recommendation systems exist, no mature production system reliably performs the full end-to-end task of selecting and modifying genetic research methods at expert quality. Tools like semantic search and citation analysis support the process but do not independently make sound methodological choices.
Technical feasibility todayclaude-sonnet-53/5Deployed tools (e.g., literature-summarization AI, research copilots) are used by scientists today, but they still have notable error rates in nuanced method selection and require expert verification, limiting full reliability.

Design and maintain genetics computer databases.

40

CI 25–55 · exposure 38 · augmentation 63 · importance 3.0/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Genetics research remains predominantly managed by human specialists with incremental tooling improvements; adoption of autonomous AI-driven database design and maintenance is rare and typically limited to routine maintenance tasks rather than strategic database work.
Sector adoption velocityclaude-sonnet-53/5Life sciences and genomics research organizations are adopting AI coding tools and data pipeline automation steadily, though full database architecture work still often involves specialized bioinformatics staff.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist geneticists with routine tasks like query optimization, anomaly detection, and backup scheduling, improving productivity on parts of database maintenance, but strategic design and complex restructuring remain human-driven.
Augmentation potentialclaude-sonnet-54/5AI coding assistants substantially speed up schema design, query writing, and database maintenance scripting, letting geneticists focus on data modeling decisions and biological validation.
Task automatabilityclaude-haiku-4-5-202510012/5Database schema design and maintenance require significant human judgment about data structures, biological semantics, and evolving research needs. While AI can assist with routine updates and schema optimization queries, end-to-end design of complex genetics databases with ≥50% time savings at equal quality is beyond current capabilities.
Task automatabilityclaude-sonnet-53/5AI coding assistants can generate schemas, scripts, and maintenance code, saving significant time, but database design requires domain-specific decisions about data models and biological semantics that still need expert oversight.
Adoption barriersclaude-haiku-4-5-202510014/5Significant barriers exist: regulatory requirements for data integrity in biomedical research, liability for data errors affecting scientific validity, institutional governance over research databases, and the need for domain expert sign-off on schema and access policies.
Adoption barriersclaude-sonnet-52/5No licensing requirement mandates a human for database design, though data integrity, research reproducibility, and organizational IT policies create some friction against full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI tools for database management exist but require significant specialist oversight and customization by geneticists, making the total cost (AI + expert labor) comparable to or exceeding a human database administrator's loaded wage for equivalent output quality.
Cost vs. human wageclaude-sonnet-53/5AI coding assistance reduces development and maintenance time meaningfully, but integration, validation, and domain expertise oversight keep costs roughly comparable to a skilled bioinformatician's time when done properly.
Technical feasibility todayclaude-haiku-4-5-202510012/5No deployed product reliably designs and maintains specialized genetics databases end-to-end; existing tools are narrow (SQL optimization, backup automation) rather than comprehensive. Production systems require human geneticists to architect and oversee database decisions.
Technical feasibility todayclaude-sonnet-53/5Products like GitHub Copilot and specialized bioinformatics tools assist with database scripting and maintenance tasks today, but no deployed system autonomously designs and maintains full genetics databases end-to-end reliably.

Write grants and papers or attend fundraising events to seek research funds.

37

CI 25–50 · exposure 38 · augmentation 63 · importance 4.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Adoption of AI for grant-writing support in academic research remains nascent and pilot-stage. Most geneticists and research institutions still rely on traditional grant-writing practices and human expertise; production-scale AI-driven fundraising is rare, and sectors are cautious about delegating high-stakes funding activities.
Sector adoption velocityclaude-sonnet-53/5Academic and research sectors are adopting AI writing assistants steadily but cautiously, with policies varying by institution and funding body; adoption is real but not yet deep or standardized.
Augmentation potentialclaude-haiku-4-5-202510013/5AI offers useful assistance in drafting, editing, and organizing grant sections, and can help identify relevant funding opportunities. However, the augmentation is limited to content support; AI does not meaningfully assist with the strategic research positioning, relationship-building, or in-person fundraising events that are central to the task.
Augmentation potentialclaude-sonnet-54/5AI significantly speeds up drafting, editing, and structuring of grants and papers, letting researchers focus more time on strategy, science content, and relationship-building at events.
Task automatabilityclaude-haiku-4-5-202510012/5Grant writing and fundraising require domain expertise, novel research positioning, and persuasive argumentation tailored to specific funding bodies. While AI can draft sections and improve clarity, it cannot independently identify fundable research directions or make the strategic decisions that distinguish successful proposals. Fundraising events require real-time networking and relationship-building that AI cannot perform.
Task automatabilityclaude-sonnet-53/5AI can draft substantial portions of grant proposals and papers (background, methods framing, literature summaries) but final scientific framing, novel argumentation, and fundraising event attendance require human presence and judgment, limiting full end-to-end automation.
Adoption barriersclaude-haiku-4-5-202510014/5Grant and fundraising decisions carry substantial reputational, institutional, and career risk. Funding agencies expect to engage directly with the research team, and many explicitly require human signatures and presence at events. Organizational and funder preferences for human-led pitching create strong adoption friction.
Adoption barriersclaude-sonnet-53/5No licensing requirement blocks AI-assisted writing, but funding agencies expect PI authorship, integrity/originality standards, and human accountability for grant content, plus fundraising events inherently require in-person human interaction.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI can reduce drafting time, but the loaded cost of a geneticist's time is high, and AI oversight and human revision still consume significant effort. The small time savings from AI assistance do not approach an order-of-magnitude cost advantage; human expertise remains the dominant cost.
Cost vs. human wageclaude-sonnet-53/5AI drafting tools are cheap per query, but the overall task still requires substantial researcher time for review, strategy, and networking, so total cost savings are moderate rather than order-of-magnitude.
Technical feasibility todayclaude-haiku-4-5-202510012/5No deployed product reliably handles end-to-end grant writing or fundraising. AI tools (ChatGPT, Claude) assist with drafting and editing, but organizations still depend on humans for proposal strategy, institutional knowledge, and the actual attendance and networking at fundraising events. Error rates on domain-specific and novel claims remain material.
Technical feasibility todayclaude-sonnet-53/5Deployed LLM tools (e.g., ChatGPT, specialized grant-writing assistants) are used in labs today for drafting sections, but reliability for full grant narratives is inconsistent and human review/rewriting is standard practice.

Confer with information technology specialists to develop computer applications for genetic data analysis.

32

CI 28–38 · exposure 25 · augmentation 75 · importance 3.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510013/5Genetics and biotech organizations use AI coding assistants increasingly for development support, but these collaborations remain largely human-led with AI in an assistive role. Production-scale AI-driven application design for genetic data pipelines is not yet commonplace.
Sector adoption velocityclaude-sonnet-53/5Bioinformatics and genomics sectors are adopting AI coding and data tools at a moderate pace, with pilots common but full agentic collaboration still rare.
Augmentation potentialclaude-haiku-4-5-202510014/5AI can substantially augment this collaboration by rapidly generating code templates, suggesting database schemas, drafting documentation, and identifying best practices in genetic data standards. Geneticists and IT specialists using AI assistants can move faster while retaining full authority over requirements and design decisions.
Augmentation potentialclaude-sonnet-54/5AI coding assistants and data analysis copilots can meaningfully speed up development of genetic data applications, aiding both geneticists and IT specialists in specification and prototyping.
Task automatabilityclaude-haiku-4-5-202510012/5This task requires domain-specific collaboration between geneticists and IT specialists to design custom applications. While AI can assist in code generation and documentation, the strategic planning, requirements definition, and cross-domain decision-making typically involve human judgment and iterative negotiation that current systems cannot fully replace while maintaining equal quality.
Task automatabilityclaude-sonnet-52/5This is a collaborative, communicative task involving requirements gathering and cross-disciplinary translation between domain science and software engineering, which AI cannot fully replace end-to-end.",
Adoption barriersclaude-haiku-4-5-202510014/5Strong barriers exist: software IP ownership, regulatory compliance (HIPAA, GDPR), institutional review board requirements, and the need for human-accountable IT and scientific leadership in designing systems for sensitive genomic data create high friction against full automation.
Adoption barriersclaude-sonnet-52/5No licensing requirement blocks this, but organizational friction and need for domain trust between geneticists and IT teams create moderate barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI coding assistants reduce development time modestly but do not approach order-of-magnitude savings when accounting for oversight, rework, and validation by qualified geneticist-IT specialist teams. The specialized nature of genetic data pipelines limits cost advantage.
Cost vs. human wageclaude-sonnet-52/5Human expert consultation and interdisciplinary judgment remain necessary, so AI tools only marginally reduce cost versus the loaded cost of skilled personnel involved.
Technical feasibility todayclaude-haiku-4-5-202510012/5Deployed AI tools can help draft code snippets and documentation, but no production system reliably orchestrates end-to-end software requirements gathering, architecture design, and stakeholder alignment for specialized genetic data applications. Current AI lacks the deep domain context needed for these conversations.
Technical feasibility todayclaude-sonnet-52/5AI coding assistants can help draft specs or code snippets but no deployed product autonomously confers with IT specialists or manages this collaborative process reliably.

Analyze determinants responsible for specific inherited traits, and devise methods for altering traits or producing new traits.

32

CI 25–39 · exposure 30 · augmentation 75 · importance 4.1/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Genetics research is slow to adopt fully autonomous AI workflows due to regulatory, ethical, and technical constraints. While genomic analysis tools are widely used, adoption of AI-driven trait design and engineering remains limited to academic pilots and early-stage biotech; production-scale autonomous use is rare.
Sector adoption velocityclaude-sonnet-52/5Academic and biotech research sectors are experimenting with AI tools (e.g., AlphaFold, gene-editing design tools) but adoption for full research task automation remains at the pilot stage, not deep production.
Augmentation potentialclaude-haiku-4-5-202510014/5AI significantly augments geneticist productivity by rapidly analyzing large genomic datasets, predicting functional consequences, and suggesting candidate variants or modifications. Geneticists leverage these tools to accelerate hypothesis generation and data interpretation while retaining experimental design and validation authority.
Augmentation potentialclaude-sonnet-54/5AI substantially aids geneticists by analyzing large genomic datasets, predicting gene function, and suggesting candidate targets for trait alteration, significantly accelerating parts of the research process.
Task automatabilityclaude-haiku-4-5-202510012/5While AI excels at analyzing genomic data and identifying genetic variants associated with traits, the core task of devising novel methods for altering or producing new traits requires experimental design, wet-lab validation, and iterative problem-solving that current AI cannot execute end-to-end. AI can accelerate analysis phases but cannot independently run experiments or navigate the complexity of trait engineering without human supervision.
Task automatabilityclaude-sonnet-52/5This task involves original scientific hypothesis generation, experimental design, and novel genetic engineering strategies that require deep domain judgment and creativity beyond current AI capabilities.dmail AI can assist with data analysis but cannot autonomously devise and validate novel trait-altering methods end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory frameworks (FDA oversight of genetic therapies, biosafety review boards, IRB approval for human studies) and institutional gatekeeping create substantial barriers to deploying autonomous trait-alteration methods. Liability for unintended consequences and the requirement for expert human oversight and sign-off are structural, not merely procedural.
Adoption barriersclaude-sonnet-53/5No licensing requirement specifically for this analytical task, but institutional review, biosafety regulations, and peer validation create meaningful friction against fully autonomous AI-driven trait engineering.
Cost vs. human wageclaude-haiku-4-5-202510013/5AI-powered genomic analysis is cost-effective compared to traditional sequencing and initial variant discovery, but the full task—including experimental design, synthesis, validation, and iteration—still requires expensive wet-lab work and human expertise, keeping total costs in the same ballpark as traditional geneticist labor.
Cost vs. human wageclaude-sonnet-52/5While AI can cheaply process genomic data, the overall task requires expert oversight, wet-lab validation, and iterative human judgment, keeping all-in costs comparable to or only modestly below human-led research costs.
Technical feasibility todayclaude-haiku-4-5-202510013/5Deployed products (genomic analysis platforms, variant prediction tools) reliably assist in trait analysis, but no current system independently devises and validates novel trait-alteration methods. These tools operate within defined pipelines; they do not conduct the creative, experimental design work that defines the full task.
Technical feasibility todayclaude-sonnet-52/5Some AI tools (e.g., protein structure prediction, sequence analysis) are deployed in genomics research, but no product autonomously analyzes trait determinants and devises novel genetic modification strategies reliably in production.

Plan or conduct basic genomic and biological research related to areas such as regulation of gene expression, protein interactions, metabolic networks, and nucleic acid or protein complexes.

29

CI 25–32 · exposure 25 · augmentation 75 · importance 4.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5While computational biology tools are widely adopted in research labs, actual displacement of geneticists' planning and conduct work is minimal. AI augments specific analytical steps but does not drive replacement; adoption is scattered and incremental rather than sector-wide and rapid.
Sector adoption velocityclaude-sonnet-53/5Life sciences research is adopting AI tools (protein folding, literature mining, data analysis) at a moderate pace, though full automation of research planning remains rare.
Augmentation potentialclaude-haiku-4-5-202510014/5AI significantly assists geneticists through structure prediction (AlphaFold), sequence analysis, pathway modeling, and literature mining. These tools substantially boost productivity on core research tasks while the scientist remains responsible for hypothesis, design, and interpretation—a strong augmentation profile.
Augmentation potentialclaude-sonnet-54/5AI substantially aids literature review, bioinformatics analysis, hypothesis generation, and structural prediction, meaningfully boosting researcher productivity while humans retain scientific oversight.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can assist with literature review, sequence analysis, and computational modeling of protein interactions, the task requires hypothesis formulation, experimental design choices, and interpretation of novel results that demand human scientific judgment. End-to-end automation with ≥50% time savings at equal quality is not achievable with current systems.
Task automatabilityclaude-sonnet-52/5Basic research planning and hypothesis-driven experimental design require deep domain judgment, novel insight, and physical wet-lab work that current AI cannot autonomously execute end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Significant barriers exist: institutional biosafety review boards (IRBs) and scientific oversight require human researchers to take responsibility for experimental design and execution. Funding agencies and peer review expect human expertise and judgment. Liability and error costs in novel research fall on the responsible scientist, not an algorithm.
Adoption barriersclaude-sonnet-53/5No licensing requirement per se, but institutional review, funding accountability, and scientific credibility norms mean human researchers must lead and validate research.
Cost vs. human wageclaude-haiku-4-5-202510012/5Computational tools reduce some costs (sequence analysis, structure prediction), but salaries for qualified geneticists remain high, and current AI tools do not eliminate the need for trained personnel to design, oversee, and validate research. The cost advantage is partial, not substantial.
Cost vs. human wageclaude-sonnet-52/5Skilled genomicists remain essential for experimental design and interpretation; AI tools reduce some analysis costs but overall research still requires expensive human expertise and lab infrastructure.
Technical feasibility todayclaude-haiku-4-5-202510012/5Deployed products (e.g., AlphaFold, sequence alignment tools, bioinformatics pipelines) handle specific subtasks reliably, but the full planning and conduct of novel genomic research requires human researchers to design experiments, troubleshoot, and validate findings. No end-to-end research execution system exists in production.
Technical feasibility todayclaude-sonnet-52/5AI tools (e.g., AlphaFold, sequence analysis models) assist specific sub-steps like structure prediction, but no deployed product independently plans or conducts full genomic research programs.

Develop protocols to improve existing genetic techniques or to incorporate new diagnostic procedures.

29

CI 25–32 · exposure 25 · augmentation 75 · importance 3.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5While bioinformatics tools are increasingly used in research, the adoption of AI for autonomous protocol development in genetics remains limited and pilot-stage; most institutions still rely on human geneticists for protocol design and regulatory validation.
Sector adoption velocityclaude-sonnet-53/5Biotech and genomics sectors are adopting AI tools for sequence analysis and literature mining at a moderate pace, but full protocol development remains largely human-driven with pilots more common than production use.
Augmentation potentialclaude-haiku-4-5-202510014/5AI systems already meaningfully assist geneticists by accelerating literature synthesis, analyzing sequence data, suggesting design improvements, and simulating protocol outcomes—substantially improving productivity while geneticists retain expert judgment and final decision authority.
Augmentation potentialclaude-sonnet-54/5AI can meaningfully assist by summarizing relevant literature, suggesting experimental designs, analyzing genetic data patterns, and drafting documentation, significantly speeding up parts of the protocol development process.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can assist in literature review, data analysis, and protocol design suggestions, developing novel genetic techniques requires expert judgment, laboratory validation, and creative problem-solving that current AI cannot fully automate end-to-end. AI tools support the process but cannot independently conceive and validate new diagnostic procedures.
Task automatabilityclaude-sonnet-52/5This requires deep scientific judgment, hands-on validation, and creative experimental design that current AI cannot fully replace, though it can assist with literature synthesis and drafting protocol sections.
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory requirements (FDA, IRB approval for diagnostic procedures), liability concerns for faulty protocols affecting patient care, and the necessity for a licensed professional to validate and sign off on diagnostic protocols create substantial legal and organizational barriers to full automation.
Adoption barriersclaude-sonnet-53/5While no explicit licensing requirement blocks AI use for protocol drafting, clinical diagnostic protocols require rigorous validation, regulatory review (e.g., CLIA/FDA), and expert sign-off, creating moderate barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI tools for protocol development are still specialized and require integration with human expertise; the combined cost of AI infrastructure, validation, and required geneticist oversight remains comparable to or exceeds the cost of a human geneticist developing the protocol directly.
Cost vs. human wageclaude-sonnet-52/5Skilled geneticist labor is expensive, but the AI component still requires substantial expert oversight, lab validation, and iteration, so overall cost savings are modest rather than order-of-magnitude.
Technical feasibility todayclaude-haiku-4-5-202510012/5Some AI products exist for bioinformatics analysis and protocol suggestions, but no deployed system reliably develops complete genetic protocols from scratch. Existing tools are narrow in scope and require significant human expert oversight and wet-lab validation before protocols are viable.
Technical feasibility todayclaude-sonnet-52/5No deployed product autonomously develops validated genetic diagnostic protocols; existing AI tools are research-stage aids for literature review or sequence analysis, not end-to-end protocol developers.

Instruct medical students, graduate students, or others in methods or procedures for diagnosis and management of genetic disorders.

28

CI 25–30 · exposure 30 · augmentation 75 · importance 3.6/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Academic medicine and graduate programs move deliberately on curriculum changes, and live instruction by domain experts remains the standard despite some adoption of AI-assisted tools; replacement of human teaching in genetic disorders lags significantly behind information-sector automation.
Sector adoption velocityclaude-sonnet-52/5Medical education is adopting AI slowly for supplementary tools (quizzes, case simulations) but core teaching and mentorship roles remain human-led with limited production-scale deployment.
Augmentation potentialclaude-haiku-4-5-202510014/5AI can substantially assist instructors by generating case studies, predicting student weak points, drafting explanatory materials, and providing practice scenarios, allowing faculty to focus on live mentoring and judgment; this augmentation is already emerging in medical education platforms.
Augmentation potentialclaude-sonnet-54/5AI can generate case studies, practice questions, explanations of genetic mechanisms, and personalized study aids, meaningfully supporting instructors and learners without replacing the instructor role.
Task automatabilityclaude-haiku-4-5-202510012/5Teaching complex clinical procedures and diagnostic reasoning requires real-time interaction, adaptive explanation, and responsiveness to student confusion. While AI can generate lecture content or practice problems, it cannot replicate the mentoring, live demonstration, and feedback loops that define effective medical education, nor can it reach the 50% time-saving threshold for the full instructional task.
Task automatabilityclaude-sonnet-52/5Teaching genetics involves live demonstration, clinical case discussion, and adaptive mentoring that AI cannot fully replace, though AI can generate materials and explanations for portions of content delivery.:
Adoption barriersclaude-haiku-4-5-202510014/5Medical education is heavily regulated by accrediting bodies, and instruction in diagnostic and management procedures typically requires a credentialed instructor to maintain program accreditation and assume clinical and educational liability; institutional and legal requirements strongly protect this role.
Adoption barriersclaude-sonnet-54/5Medical education requires accredited, often licensed faculty to certify competency and sign off on clinical training, creating strong institutional and accreditation barriers to AI substitution.
Cost vs. human wageclaude-haiku-4-5-202510012/5Developing and maintaining AI-generated educational content is costly upfront, and instructors would still be required for supervision, assessment, and credentialing; the all-in cost of AI tutoring systems compared to a geneticist's time is not clearly favorable, especially given institutional oversight needs.
Cost vs. human wageclaude-sonnet-52/5Creating high-quality instructional content and case-based teaching still requires expert oversight and validation, so cost savings versus a qualified instructor are modest once quality assurance is factored in.
Technical feasibility todayclaude-haiku-4-5-202510013/5AI systems exist that can generate educational materials, practice case scenarios, and assessments for genetic topics; however, no deployed product reliably replaces a qualified instructor for live teaching, hands-on procedure demonstration, or clinical judgment modeling where accuracy and liability matter.
Technical feasibility todayclaude-sonnet-52/5AI tutoring and content-generation tools exist and are used to supplement medical education, but no deployed product independently instructs students in diagnosis/management of genetic disorders at the level of a geneticist mentor.

Evaluate, diagnose, or treat genetic diseases.

26

CI 20–32 · exposure 30 · augmentation 75 · importance 3.7/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510013/5Major medical centers and clinical labs have integrated AI-assisted variant interpretation pipelines, but adoption is uneven and largely limited to tool-assisted workflows rather than autonomous decision-making. Production use is growing but constrained by regulatory and liability requirements.
Sector adoption velocityclaude-sonnet-52/5Healthcare and clinical genetics adopt AI cautiously due to regulatory hurdles, patient safety concerns, and slower institutional adoption cycles despite growing genomics AI tools.
Augmentation potentialclaude-haiku-4-5-202510014/5AI significantly augments geneticist productivity through rapid variant annotation, literature mining, and phenotype-to-gene matching, allowing experts to focus on complex interpretation and clinical correlation. These tools materially raise throughput and decision quality while the human remains central.
Augmentation potentialclaude-sonnet-54/5AI significantly aids variant interpretation, literature review, and diagnostic hypothesis generation, meaningfully boosting geneticist productivity while the clinician remains responsible for final diagnosis and treatment.
Task automatabilityclaude-haiku-4-5-202510012/5AI can assist in variant interpretation and flagging pathogenic mutations using databases like ClinVar, but evaluation and diagnosis of genetic diseases requires integrating clinical phenotype, family history, and complex multi-gene interactions that currently demand human expert judgment. End-to-end automation with 50% time savings at equal quality is not demonstrated.
Task automatabilityclaude-sonnet-52/5Genetic disease evaluation and treatment involves complex clinical judgment, patient history integration, and decision-making that current AI cannot perform end-to-end; AI can assist with variant interpretation but not full diagnosis/treatment autonomously.
Adoption barriersclaude-haiku-4-5-202510014/5Genetic diagnosis and treatment decisions are heavily regulated; clinical laboratories must be CLIA-certified and employ licensed genetic counselors and physicians who must legally validate and communicate results. Liability for missed or misinterpreted diagnoses creates strong error-cost asymmetry favoring human oversight.
Adoption barriersclaude-sonnet-55/5Diagnosing and treating genetic diseases requires licensed physician/geneticist involvement, with strict regulatory, malpractice liability, and clinical governance requirements.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI tools for variant annotation and filtering are cost-effective, but comprehensive genetic diagnosis still requires substantial human geneticist time for case review, phenotype matching, and clinical correlation. The all-in cost per diagnosis remains comparable to or higher than human-only workflows.
Cost vs. human wageclaude-sonnet-52/5AI tools can reduce some analysis costs but the overall clinical workflow still requires expensive specialist oversight, genetic counseling, and lab validation, keeping costs comparable to human-driven care.
Technical feasibility todayclaude-haiku-4-5-202510013/5Diagnostic support tools exist (e.g., sequence annotation pipelines, variant effect predictors) and are used in clinical labs, but they operate as narrow support systems requiring human review rather than independent diagnostic systems. Material error rates and need for expert sign-off limit full autonomy.
Technical feasibility todayclaude-sonnet-52/5Some deployed tools help interpret genomic variants (e.g., ACMG classifiers) but no product independently diagnoses or treats genetic diseases in production without physician oversight.

Participate in the development of endangered species breeding programs or species survival plans.

26

CI 5–47 · exposure 33 · augmentation 63 · importance 2.8/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Adoption is slow and limited; endangered species programs are typically small-scale, run by zoos and conservation nonprofits with constrained budgets and limited digitization. Integration of AI into breeding decisions remains uncommon in practice, though academic pilots exist. Organizational friction is high: trust in AI for irreversible breeding decisions is low, and many institutions lack the technical infrastructure.
Sector adoption velocityclaude-sonnet-51/5Conservation biology and wildlife genetics are a low-digitization, niche scientific field with minimal AI agent deployment in production settings.
Augmentation potentialclaude-haiku-4-5-202510014/5AI significantly augments geneticists' capabilities today: rapid analysis of vast genomic datasets, predictive modeling of breeding outcomes, identification of genetic diversity hotspots, and scenario planning for population trajectories. These tools allow experts to explore more options and make faster, better-informed decisions while retaining full oversight and judgment on conservation strategy.
Augmentation potentialclaude-sonnet-53/5AI can assist with population genetics modeling, data analysis, and simulation of breeding outcomes, providing meaningful support to specialists who still drive program design.
Task automatabilityclaude-haiku-4-5-202510014/5AI can handle substantial portions of this task: analyzing genetic data to predict breeding outcomes, modeling population dynamics, identifying optimal breeding pairs, and generating survival plans based on historical and genetic parameters. However, the task requires expert judgment on species-specific biological constraints, coordination with multiple institutions, and adaptive decision-making during unforeseen breeding failures or environmental changes, preventing full 100% automation.
Task automatabilityclaude-sonnet-51/5This task requires field expertise, ecological judgment, interspecies collaboration, and strategic decision-making across institutions; AI cannot perform this end-to-end today.
Adoption barriersclaude-haiku-4-5-202510014/5Significant barriers exist: regulatory oversight by wildlife agencies and international treaties (CITES, ESA) that mandate human expert review; liability for species outcomes; reputational risk if AI-guided breeding fails; and institutional/zoo networks that require coordinated human decision-making. Regulatory frameworks generally require geneticists to be responsible for and sign off on breeding recommendations.
Adoption barriersclaude-sonnet-54/5Conservation decisions often involve regulatory oversight (e.g., endangered species law), interagency coordination, and expert sign-off, creating substantial institutional and legal barriers to automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5While AI reduces computational and data-processing costs, species survival programs require intensive expert oversight, field coordination, and adaptive management that demand experienced human geneticists. The all-in cost (AI inference + integration + human oversight + operational coordination) remains comparable to or higher than employing dedicated geneticists for these high-stakes, low-volume conservation efforts.
Cost vs. human wageclaude-sonnet-51/5There is no AI system substituting for the human expert labor here, so cost comparison favors humans entirely; AI cannot produce the output alone.
Technical feasibility todayclaude-haiku-4-5-202510013/5Deployed AI tools (genetic analysis software, population modeling platforms) perform parts of this task reliably in production (e.g., genomic sequencing analysis, pedigree reconstruction). However, integrated end-to-end species survival planning via AI remains narrow in scope; most systems support rather than replace geneticists' strategic decisions, and outcomes depend heavily on data quality and expert interpretation.
Technical feasibility todayclaude-sonnet-51/5No deployed product plans or manages breeding programs or species survival plans; this remains a human expert-driven, institutionally coordinated process.

Conduct family medical studies to evaluate the genetic basis for traits or diseases.

25

CI 25–25 · exposure 25 · augmentation 75 · importance 3.1/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Genomic research organizations adopt AI for data analysis and interpretation, but family study design and conduct remain slow to automate due to regulatory oversight, customized clinical protocols, and the need for expert hypothesis-driven research. Adoption is limited to analytical components, not full study execution.
Sector adoption velocityclaude-sonnet-52/5Academic medicine and genetics research adopt AI tools for analysis but the field is conservative regarding human-subjects research protocols, resulting in slow, uneven adoption of end-to-end automation.
Augmentation potentialclaude-haiku-4-5-202510014/5AI substantially augments geneticists' productivity through automated variant calling, inheritance pattern detection, literature synthesis, and statistical modeling, allowing experts to focus on clinical interpretation, study design, and novel insights. The human geneticist becomes more efficient and thorough with AI assistance.
Augmentation potentialclaude-sonnet-54/5AI significantly aids genetic study by automating variant calling, statistical genetic analysis, literature review, and pattern detection in family pedigrees, substantially boosting geneticists' productivity while they retain oversight.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can accelerate data analysis (variant annotation, statistical inheritance pattern detection) and literature review, the core task demands expert clinical judgment to design studies, interpret complex family histories, formulate hypotheses, and evaluate causality—steps that require human expertise and cannot be fully automated today.
Task automatabilityclaude-sonnet-52/5This task involves designing studies, recruiting families, collecting pedigree and clinical data, and interpreting genetic findings in clinical/biological context—activities requiring human judgment, ethics oversight, and field-level coordination that current AI cannot fully replace. AI can assist with data analysis portions but not the full study conduct.
Adoption barriersclaude-haiku-4-5-202510014/5Significant regulatory and ethical barriers exist: IRB approval, informed consent protocols, HIPAA compliance, clinical laboratory licensing requirements, and professional liability standards all require human geneticists to design, authorize, and sign off on family studies. Medical decision-making and patient contact are legally protected.
Adoption barriersclaude-sonnet-54/5Human subjects research requires IRB approval, informed consent processes, and licensed genetic counselors/physicians for clinical interpretation, creating significant regulatory and ethical barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI genomic analysis and data processing are cost-effective for their components, but the full study conduct involves laboratory work, clinical assessments, and expert geneticist time that dominate costs. Integration of AI tools into existing workflows adds overhead relative to the portion of labor saved.
Cost vs. human wageclaude-sonnet-52/5While computational analysis costs are low, the human-intensive components (recruiting, interviewing families, clinical assessment, ethical oversight) still require substantial human labor, keeping overall cost comparable to or only modestly better than fully human-led studies.
Technical feasibility todayclaude-haiku-4-5-202510012/5AI tools exist for genomic analysis and pattern recognition in medical data, but no deployed product reliably conducts the entire family medical study end-to-end, including study design, participant recruitment/evaluation, and causal inference. Current systems are narrow, research-focused, and require substantial expert oversight.
Technical feasibility todayclaude-sonnet-52/5AI tools exist for genomic data analysis and variant interpretation, but no deployed product conducts complete family medical studies including participant recruitment, consent, and clinical correlation reliably in production.

Extract deoxyribonucleic acid (DNA) or perform diagnostic tests involving processes such as gel electrophoresis, Southern blot analysis, and polymerase chain reaction analysis.

25

CI 20–30 · exposure 20 · augmentation 50 · importance 4.1/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5While medical laboratories use robotics and automation, adoption of end-to-end autonomous diagnostic testing remains limited; most facilities still rely on human technicians for protocol execution, quality assurance, and result interpretation, reflecting slow production-level displacement in clinical genetics.
Sector adoption velocityclaude-sonnet-52/5Clinical and research genetics labs are gradually adopting automated liquid handlers and robotic PCR setups, but adoption of AI-driven end-to-end wet lab automation remains slow and capital-intensive compared to digital-sector AI adoption.
Augmentation potentialclaude-haiku-4-5-202510013/5AI and laboratory information systems assist geneticists in data analysis, protocol optimization, and result interpretation, but the hands-on experimental execution remains human-driven; AI augmentation is useful for the analytical and computational portions but does not significantly enhance the physical experimental work itself.
Augmentation potentialclaude-sonnet-53/5AI can assist with experimental design, PCR primer design, interpreting gel/blot images, and analyzing sequencing data, meaningfully augmenting the surrounding analytical work even though it doesn't perform the physical steps.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can assist in data interpretation and protocol design, the physical extraction and manipulation of biological samples, gel electrophoresis setup, Southern blot preparation, and PCR execution require hands-on laboratory work that current robotics and automation cannot reliably perform end-to-end without substantial human intervention and oversight.
Task automatabilityclaude-sonnet-52/5This is a physical wet-lab task requiring manual pipetting, sample handling, and equipment operation that current AI systems cannot perform without robotic lab automation, which is not standard AI deployment.'
Adoption barriersclaude-haiku-4-5-202510014/5Clinical diagnostic testing is heavily regulated (CLIA, CAP standards), requires licensed personnel to validate and sign off on results, and involves liability for error; regulatory frameworks mandate human expertise and accountability, creating substantial legal and compliance barriers to full automation.
Adoption barriersclaude-sonnet-53/5No licensing barrier per se, but physical infrastructure, biosafety protocols, and quality-control/regulatory requirements around diagnostic testing create moderate friction against wholesale automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5Laboratory automation equipment and integration costs are high, and human geneticists and technicians remain cheaper for complex diagnostic work; only highly repetitive, standardized assays achieve cost parity or better, which is not the case for diverse diagnostic testing.
Cost vs. human wageclaude-sonnet-52/5Lab automation robotics can reduce costs at scale in large facilities, but AI itself (software/models) does not substitute for the physical process, and setup costs for robotic wet-lab automation are high relative to a technician's wage for typical volumes.
Technical feasibility todayclaude-haiku-4-5-202510012/5Some laboratory automation exists for specific steps (e.g., liquid handling, PCR cycling), but no deployed product performs the full diagnostic workflow reliably without human technicians for sample preparation, quality control, and troubleshooting; most deployed solutions handle only narrow sub-tasks.
Technical feasibility todayclaude-sonnet-51/5No general AI product performs DNA extraction or wet-lab diagnostic assays; some specialized lab robotics exist but these are automation hardware, not AI systems, and are not widely deployed for this exact task.

Design sampling plans or coordinate the field collection of samples such as tissue specimens.

23

CI 16–30 · exposure 20 · augmentation 63 · importance 3.2/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Life sciences and biotech are moderately digitized but sampling coordination remains largely manual and customized per project; adoption of AI for this task is still in pilot phases rather than production deployment across the sector.
Sector adoption velocityclaude-sonnet-52/5Life sciences and field biology are slower to adopt AI agents for physical and logistical tasks compared to purely digital/information sectors.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can usefully augment by generating candidate sampling designs, optimizing sample sizes, and drafting collection protocols, meaningfully raising geneticist productivity in the planning phase while humans retain judgment on feasibility and regulatory fit.
Augmentation potentialclaude-sonnet-54/5AI can meaningfully assist in designing statistically sound sampling plans, optimizing site selection, and analyzing spatial/temporal data, even though field execution remains human-driven.
Task automatabilityclaude-haiku-4-5-202510012/5AI can assist with statistical design of sampling plans and suggest collection protocols based on literature, but the task fundamentally requires domain expertise, field judgment, and real-world coordination with lab staff and field crews that current systems cannot fully execute end-to-end.
Task automatabilityclaude-sonnet-52/5Physical field collection and much of sampling plan design require domain judgment, site logistics, and physical presence that current AI cannot perform end-to-end.'
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory compliance, institutional review boards, sample chain-of-custody requirements, and the need for qualified personnel signatures on collection protocols create substantial barriers to full automation.
Adoption barriersclaude-sonnet-53/5While not formally licensed, sampling plans often require scientific expertise, ethical/regulatory approvals (IRB, permits), and physical access, creating moderate friction against automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5The cost of AI assistance for plan design is relatively low, but the task still requires significant human oversight, coordination, and field work that dominates total cost, making AI cost-per-task-equivalent only modestly lower than a full human execution.
Cost vs. human wageclaude-sonnet-51/5AI cannot replace the physical fieldwork and coordination costs; human geneticists/technicians remain the primary cost driver, making AI substitution not cheaper overall.
Technical feasibility todayclaude-haiku-4-5-202510012/5While AI can generate sampling schemas and draft collection procedures, deployed products lack the integration with lab information systems, field logistics, and quality control needed for reliable independent execution of this coordination task in production settings.
Technical feasibility todayclaude-sonnet-51/5No deployed product autonomously designs sampling plans or coordinates field collection of biological specimens; this remains a human-led scientific and logistical activity.

Collaborate with biologists and other professionals to conduct appropriate genetic and biochemical analyses.

19

CI 7–30 · exposure 13 · augmentation 75 · importance 3.6/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Academic and biotech sectors are relatively slow adopters of full automation in wet-lab and collaborative research contexts, despite some digital tool penetration. Most adoption remains in supporting individual analyses rather than displacing the core collaboration and judgment roles.
Sector adoption velocityclaude-sonnet-52/5Academic and biotech research settings adopt AI tools for specific analyses but interdisciplinary collaboration structures remain human-driven and slow to change.
Augmentation potentialclaude-haiku-4-5-202510014/5AI substantially enhances geneticist productivity by accelerating sequence analysis, literature mining, statistical modeling, and preliminary data interpretation while the human expert remains in the loop for design decisions and validation. These augmentation tools are increasingly deployed in research labs and clinical settings.
Augmentation potentialclaude-sonnet-54/5AI tools significantly enhance the underlying genetic and biochemical analyses (sequence analysis, literature review, data interpretation) that feed into and support this collaborative task.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can assist with data analysis and literature review components, the task requires collaborative decision-making, experimental design judgment, and real-time adaptation to results—core elements that cannot be fully automated today. Current AI cannot autonomously orchestrate the cross-disciplinary judgment and iterative problem-solving that collaboration demands.
Task automatabilityclaude-sonnet-51/5This is fundamentally a collaborative, interpersonal research coordination task requiring physical presence, scientific judgment, and relationship management that AI cannot perform end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Significant regulatory barriers exist: genetic testing and analysis often require credentialed professionals, institutional review boards oversee protocols, and liability for incorrect genetic interpretations creates high error-cost asymmetry. Professional licensing and the legal requirement for qualified human sign-off on clinical or research findings provide strong protection.
Adoption barriersclaude-sonnet-53/5While no license specifically governs 'collaboration,' scientific research protocols, institutional review, and professional accountability create moderate organizational friction against full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI tools for genetic data analysis are relatively affordable, but the loaded cost of a geneticist conducting collaborative research—especially salary plus overhead—remains lower per unit than integrating multiple specialized AI systems with required expert oversight and validation.
Cost vs. human wageclaude-sonnet-51/5AI cannot substitute for the human collaboration itself, so there is no comparable AI cost structure for this task as stated.
Technical feasibility todayclaude-haiku-4-5-202510012/5Deployed AI systems can support specific analytical subtasks (sequence alignment, some data visualization) but no production system reliably performs the full collaborative planning and biochemical analysis coordination described. The human judgment in selecting appropriate methodologies and interpreting complex results remains essential.
Technical feasibility todayclaude-sonnet-51/5No deployed product manages cross-disciplinary scientific collaboration; current AI tools assist with analysis subcomponents but not the collaborative process itself.

Verify that cytogenetic, molecular genetic, and related equipment and instrumentation is maintained in working condition to ensure accuracy and quality of experimental results.

16

CI 7–25 · exposure 13 · augmentation 38 · importance 3.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Laboratory equipment maintenance remains largely manual and checklist-driven, even in high-resource genomics labs. Adoption of AI-driven predictive maintenance is early-stage and limited to larger institutions; most labs follow traditional maintenance schedules with human verification.
Sector adoption velocityclaude-sonnet-52/5Physical lab maintenance tasks in specialized scientific settings see slow AI adoption compared to purely digital knowledge work.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist by analyzing equipment logs, flagging anomalies, and recommending preventive maintenance schedules, reducing the time a geneticist spends on routine monitoring. However, the assistant must still perform hands-on verification, so the augmentation is partial rather than transformative.
Augmentation potentialclaude-sonnet-52/5AI can help track maintenance schedules, log calibration data, or flag anomalies in equipment performance logs, but cannot replace physical verification.
Task automatabilityclaude-haiku-4-5-202510012/5While AI could assist with scheduling and log analysis, the task requires physical inspection, hands-on troubleshooting, and verification of delicate scientific instruments—core elements that cannot be automated end-to-end today. Some monitoring and alerting could be automated, but final sign-off and corrective action remain fundamentally human responsibilities.
Task automatabilityclaude-sonnet-51/5This requires physical inspection, calibration, and hands-on maintenance of laboratory instruments, which current AI cannot perform end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory standards (ISO 15189, GLP, FDA requirements for clinical labs) typically mandate that a qualified human must verify and sign off on instrument maintenance and calibration. Liability exposure for failed verification—which could invalidate experimental results or harm patients—creates strong legal and organizational barriers to unsupervised automation.
Adoption barriersclaude-sonnet-54/5Quality control and instrument calibration in clinical/research genetics settings often require documented human sign-off and adherence to lab accreditation standards, creating strong procedural barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI-assisted monitoring systems cost money to implement and integrate, while the core verification task still requires a trained geneticist or technician's time. The labor cost remains the dominant expense; AI savings are marginal and do not approach order-of-magnitude reduction.
Cost vs. human wageclaude-sonnet-51/5AI cannot substitute for the physical labor and expert judgment involved, so there is no meaningful cost comparison favoring AI.
Technical feasibility todayclaude-haiku-4-5-202510012/5No deployed product reliably performs autonomous maintenance verification of complex laboratory equipment. Predictive maintenance tools exist but do not replace the human requirement to physically validate instrument calibration, function, and data accuracy before live experiments.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product performs physical equipment maintenance and verification in genetics labs; this remains a manual, hands-on task.

Plan curatorial programs for species collections that include acquisition, distribution, maintenance, or regeneration.

13

CI 5–20 · exposure 8 · augmentation 50 · importance 2.5/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5Species collections and curatorial work are concentrated in academic and museum settings with slower digitization and limited adoption of automation technologies, reflecting traditional institutional structures and high barriers to change.
Sector adoption velocityclaude-sonnet-52/5Research and biological curation sectors have been slower to adopt AI agents for high-level strategic planning compared to information-heavy industries like finance or software.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist by analyzing collection metadata, suggesting acquisition priorities based on data analysis, or automating routine inventory checks, thereby improving a curator's productivity on data-heavy aspects while they retain decision authority.
Augmentation potentialclaude-sonnet-53/5AI tools can help analyze genetic diversity data, forecast maintenance needs, or draft planning documents, providing moderate assistance while the geneticist retains final decision-making.
Task automatabilityclaude-haiku-4-5-202510011/5This task requires strategic decision-making about living biological systems, stakeholder coordination, and complex institutional knowledge that current AI cannot perform end-to-end. While AI can assist in data analysis or cataloging, the curatorial judgment, acquisition strategies, and maintenance planning decisions demand expert human oversight.
Task automatabilityclaude-sonnet-52/5This task requires strategic planning, resource allocation, and biological judgment about species collections that AI cannot perform end-to-end; AI can assist with parts of the analysis but not the overall program design.'
Adoption barriersclaude-haiku-4-5-202510014/5Curatorial roles often require advanced degrees, institutional authority, and professional licensure or credentialing. Museums and repositories typically have legal liability for specimen integrity and regulatory compliance that necessitate human expert sign-off.
Adoption barriersclaude-sonnet-54/5Curatorial planning for genetic resources often involves regulatory compliance, biosecurity, institutional accountability, and scientific authority that require credentialed human oversight and sign-off.
Cost vs. human wageclaude-haiku-4-5-202510011/5AI would require significant human oversight and validation to be useful here, meaning the total cost (AI + human review + corrections) would exceed the cost of a skilled geneticist performing the task directly.
Cost vs. human wageclaude-sonnet-52/5Given the low feasibility, any AI contribution would only supplement rather than replace the human planner, so cost savings versus a geneticist's salary are minimal at present.
Technical feasibility todayclaude-haiku-4-5-202510011/5No deployed AI product reliably performs curatorial program planning for species collections in production. This domain requires deep domain expertise, institutional relationships, and biological judgment that current systems lack.
Technical feasibility todayclaude-sonnet-51/5No deployed product plans curatorial programs for genetic or species collections; this remains a specialized scientific and administrative function performed by human experts.

Maintain laboratory safety programs and train personnel in laboratory safety techniques.

11

CI 5–16 · exposure 5 · augmentation 50 · importance 3.5/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5Safety program maintenance in genetics labs remains heavily regulated and human-centric; adoption of AI for safety training and program management is minimal even in well-resourced institutions. Risk aversion in safety-critical domains and slow regulatory evolution limit practical deployment velocity.
Sector adoption velocityclaude-sonnet-52/5Academic and research lab settings adopt AI tools slowly for safety-critical, compliance-driven functions, with pilots rare and production deployment essentially absent.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist by generating initial safety content drafts, tracking compliance timelines, and suggesting training updates based on incident patterns or regulatory changes, helping geneticists manage documentation and scheduling more efficiently while they focus on personalized instruction and program oversight.
Augmentation potentialclaude-sonnet-53/5AI can help draft safety manuals, generate training materials, quizzes, and checklists, and track compliance records, meaningfully assisting administrative aspects of the task.
Task automatabilityclaude-haiku-4-5-202510011/5This task requires designing, updating, and personalizing safety protocols based on organizational context, regulatory changes, and staff individual needs—judgment-intensive work that AI cannot perform end-to-end today. Even with significant setup, AI cannot reliably conduct the interpersonal assessment and adaptive training necessary for effective safety program maintenance.
Task automatabilityclaude-sonnet-51/5This requires physical oversight of a lab space, hands-on demonstration of safety techniques, and accountability for compliance that current AI cannot perform end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Genetics laboratories operate under strict regulatory frameworks (OSHA, biosafety regulations, institutional biosafety committees) that require documented human responsibility for safety training and program oversight. Liability and legal accountability for safety failures create hard barriers to full AI substitution.
Adoption barriersclaude-sonnet-54/5Institutional biosafety and regulatory requirements (e.g., OSHA, IBC oversight) typically mandate designated qualified personnel to maintain and certify safety programs, creating strong organizational and compliance barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI tools for generating safety materials and scheduling training are inexpensive, but the human geneticist's oversight, customization, and delivery of safety training remains the dominant cost. Full automation would require costly integration and continuous compliance monitoring, making the total cost comparable to or exceeding human delivery.
Cost vs. human wageclaude-sonnet-51/5AI cannot substitute for the human presence, liability, and physical demonstration required, so there is no meaningful cost comparison for full task replacement.
Technical feasibility todayclaude-haiku-4-5-202510012/5While AI can generate safety documentation drafts and training content templates, no deployed product reliably manages the full program lifecycle (regulatory compliance tracking, personnel assessment, adaptive intervention) in production genetics labs. Current systems lack the domain-specific reliability needed for safety-critical training delivery.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product manages laboratory safety programs or conducts hands-on personnel training; this remains a human supervisory and instructional role.

Supervise or direct the work of other geneticists, biologists, technicians, or biometricians working on genetics research projects.

4

CI 0–7 · exposure 0 · augmentation 38 · importance 4.5/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5Research institutions have not adopted AI for supervisory roles over geneticists or research teams; this remains a distinctly human, high-discretion function in academic and industrial genetics labs.
Sector adoption velocityclaude-sonnet-52/5Academic and biotech research settings adopt AI tools for data analysis but not for human personnel supervision, which remains untouched by automation trends.
Augmentation potentialclaude-haiku-4-5-202510012/5AI could potentially assist with data reporting, scheduling, or literature reviews to reduce administrative burden on supervisors, but these are minor aids to the core supervisory function rather than transformative augmentation of the supervision task itself.
Augmentation potentialclaude-sonnet-53/5AI can help with scheduling, progress tracking, literature synthesis, and drafting reports that support a supervisor's oversight tasks, offering moderate productivity gains.
Task automatabilityclaude-haiku-4-5-202510011/5Supervising research staff requires judgment about personnel performance, strategic research direction, conflict resolution, and mentoring—elements that demand contextual understanding of individual capabilities and project nuance that current AI cannot perform end-to-end.
Task automatabilityclaude-sonnet-51/5Supervising and directing research staff requires interpersonal management, mentorship, and real-time judgment calls that current AI cannot perform end-to-end.dummy no product replaces this managerial function.
Adoption barriersclaude-haiku-4-5-202510015/5Personnel supervision and research direction carry legal, fiduciary, and institutional accountability that must rest with a licensed scientist or credentialed manager; liability and employment law require human sign-off.
Adoption barriersclaude-sonnet-54/5Supervisory responsibility typically requires accountability, expertise credentials, and legal/organizational authority that cannot be delegated to a non-human system.
Cost vs. human wageclaude-haiku-4-5-202510011/5This task requires a human with deep scientific expertise and institutional authority; AI has no cost advantage when the alternative is hiring a qualified supervisor with accountability and judgment authority.
Cost vs. human wageclaude-sonnet-51/5There is no AI substitute performing this supervisory role, so no meaningful cost comparison exists; the human cost is the only option.
Technical feasibility todayclaude-haiku-4-5-202510011/5No deployed AI product can reliably manage personnel supervision, performance reviews, project prioritization, or mentoring at the quality and accountability required in research settings today.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product manages or directs human research teams in genetics labs; this remains purely a human management function.

Related occupations — Life, Physical & Social Science

How to read this

A high substitution score does not mean this job disappears — it means a large share of its current tasks face replacement pressure, so the mix of tasks is likely to change. High augmentation alongside substitution typically means the occupation reorganizes around the protected tasks. Wide confidence intervals mean the rater panel disagreed: treat those scores as open questions, not verdicts.

What would change this score

New model capabilities (automatability, feasibility), falling inference costs (cost ratio), regulation and licensing shifts (barriers), and measured sector adoption (velocity) all re-enter at every index release. Each release is recomputed, versioned and kept queryable — scores are claims with a date on them, not permanent labels.